This announcement is a separate document:
リボミック：umedaptanib pegol（抗FGF2アプタマー）に関する用途特許の台湾における特許査定のお知らせ
Ribomic: Notice of patent assessment in Taiwan for application patents relating to umedaptanib pegol (anti-FGF2 aptamer)
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated